Adenovirus Infections
2
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Symbio PharmaceuticalsJapan - Tokyo
2 programs1
1
cidofovirPhase 3Small Molecule1 trial
BCVPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Symbio Pharmaceuticalscidofovir
Symbio PharmaceuticalsBCV
Clinical Trials (2)
Total enrollment: 232 patients across 2 trials
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
Start: Mar 2026Est. completion: Jun 2028180 patients
Phase 3Recruiting
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
Start: Aug 2021Est. completion: Sep 202652 patients
Phase 2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 232 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.